Cargando…

Brittle Asthma: Still on Board?

(1) Background: “Brittle Asthma” was considered an asthma clinical phenotype and deemed to be life-threatening in the early 2000s; then, this definition disappeared. The purpose of this review is to examine what has historically been referred to as this term and see whether it may be applied to mode...

Descripción completa

Detalles Bibliográficos
Autores principales: Visca, Dina, Ardesi, Francesco, Centis, Rosella, Pignatti, Patrizia, Spanevello, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10669403/
https://www.ncbi.nlm.nih.gov/pubmed/38002086
http://dx.doi.org/10.3390/biomedicines11113086
_version_ 1785149229553942528
author Visca, Dina
Ardesi, Francesco
Centis, Rosella
Pignatti, Patrizia
Spanevello, Antonio
author_facet Visca, Dina
Ardesi, Francesco
Centis, Rosella
Pignatti, Patrizia
Spanevello, Antonio
author_sort Visca, Dina
collection PubMed
description (1) Background: “Brittle Asthma” was considered an asthma clinical phenotype and deemed to be life-threatening in the early 2000s; then, this definition disappeared. The purpose of this review is to examine what has historically been referred to as this term and see whether it may be applied to modern clinical practice, thus acquiring fresh relevance and meaning. (2) Methods: A non-systematic search of the literature was conducted using both MeSH and free-text phrases. No limitations on the research design or type of publication were applied. (3) Results: Reliable data regarding “Brittle Asthma” are lacking due to the paucity of current data and the few studies available. After a few years of reworking, it was divided into two sub-classes: one characterized by a wide PEF variability despite high-dose therapy and the other by sudden acute attacks in otherwise apparently normal airway functions or well-controlled asthma. Their characteristics were hardly defined because of their low prevalence. Data regarding risk factors, atopy, mechanisms, and treatments were analyzed. (4) Conclusions: Over time, different terminology has been introduced to define asthma severity and control. It would be worth investigating whether the term “Brittle Asthma” previously used may be helpful to find new hints to stratify patients and improve disease management.
format Online
Article
Text
id pubmed-10669403
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106694032023-11-17 Brittle Asthma: Still on Board? Visca, Dina Ardesi, Francesco Centis, Rosella Pignatti, Patrizia Spanevello, Antonio Biomedicines Review (1) Background: “Brittle Asthma” was considered an asthma clinical phenotype and deemed to be life-threatening in the early 2000s; then, this definition disappeared. The purpose of this review is to examine what has historically been referred to as this term and see whether it may be applied to modern clinical practice, thus acquiring fresh relevance and meaning. (2) Methods: A non-systematic search of the literature was conducted using both MeSH and free-text phrases. No limitations on the research design or type of publication were applied. (3) Results: Reliable data regarding “Brittle Asthma” are lacking due to the paucity of current data and the few studies available. After a few years of reworking, it was divided into two sub-classes: one characterized by a wide PEF variability despite high-dose therapy and the other by sudden acute attacks in otherwise apparently normal airway functions or well-controlled asthma. Their characteristics were hardly defined because of their low prevalence. Data regarding risk factors, atopy, mechanisms, and treatments were analyzed. (4) Conclusions: Over time, different terminology has been introduced to define asthma severity and control. It would be worth investigating whether the term “Brittle Asthma” previously used may be helpful to find new hints to stratify patients and improve disease management. MDPI 2023-11-17 /pmc/articles/PMC10669403/ /pubmed/38002086 http://dx.doi.org/10.3390/biomedicines11113086 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Visca, Dina
Ardesi, Francesco
Centis, Rosella
Pignatti, Patrizia
Spanevello, Antonio
Brittle Asthma: Still on Board?
title Brittle Asthma: Still on Board?
title_full Brittle Asthma: Still on Board?
title_fullStr Brittle Asthma: Still on Board?
title_full_unstemmed Brittle Asthma: Still on Board?
title_short Brittle Asthma: Still on Board?
title_sort brittle asthma: still on board?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10669403/
https://www.ncbi.nlm.nih.gov/pubmed/38002086
http://dx.doi.org/10.3390/biomedicines11113086
work_keys_str_mv AT viscadina brittleasthmastillonboard
AT ardesifrancesco brittleasthmastillonboard
AT centisrosella brittleasthmastillonboard
AT pignattipatrizia brittleasthmastillonboard
AT spanevelloantonio brittleasthmastillonboard